JNJ

234.89

+0.77%↑

UNH

275.5

-1.96%↓

ISRG

476.32

-0.68%↓

ABT

108.95

+0.36%↑

RDY

13.92

+1.09%↑

JNJ

234.89

+0.77%↑

UNH

275.5

-1.96%↓

ISRG

476.32

-0.68%↓

ABT

108.95

+0.36%↑

RDY

13.92

+1.09%↑

JNJ

234.89

+0.77%↑

UNH

275.5

-1.96%↓

ISRG

476.32

-0.68%↓

ABT

108.95

+0.36%↑

RDY

13.92

+1.09%↑

JNJ

234.89

+0.77%↑

UNH

275.5

-1.96%↓

ISRG

476.32

-0.68%↓

ABT

108.95

+0.36%↑

RDY

13.92

+1.09%↑

JNJ

234.89

+0.77%↑

UNH

275.5

-1.96%↓

ISRG

476.32

-0.68%↓

ABT

108.95

+0.36%↑

RDY

13.92

+1.09%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Отворен

СекторЗдравеопазване

25.93 0.35

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

25.44

Максимум

26.19

Ключови измерители
By Trading Economics
Приходи	23M 7.4M
Продажби	18M 99M
EPS	0.06
Марж на печалбата	7.468
Служители	342
EBITDA	23M 11M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+25.15% upside

Дивиденти
By Dow Jones
Следващи печалби	25.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	813M 3.2B
Предишно отваряне	25.58
Предишно затваряне	25.93

Настроения в новините

By Acuity

36%

64%

111 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.02.2026 г., 23:11 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting All-Time High -- Market Talk

3.02.2026 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Technical Correction -- Market Talk

3.02.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3.02.2026 г., 23:38 ч. UTC

Печалби

AMD Sales Climb on Help From Data-Center Business -- Update

3.02.2026 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3.02.2026 г., 23:27 ч. UTC

Придобивния, сливания и поглъщания

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3.02.2026 г., 23:25 ч. UTC

Придобивния, сливания и поглъщания

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3.02.2026 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3.02.2026 г., 23:22 ч. UTC

Придобивния, сливания и поглъщания

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3.02.2026 г., 23:19 ч. UTC

Пазарно говорене

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3.02.2026 г., 23:19 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.02.2026 г., 22:56 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3.02.2026 г., 22:40 ч. UTC

Печалби

Amdocs Extends Collaboration With T-Mobile

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q Adj EPS $1.81

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q Rev $1.16B

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q EPS $1.45 >

3.02.2026 г., 22:38 ч. UTC

Печалби

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3.02.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3.02.2026 г., 22:14 ч. UTC

Печалби

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3.02.2026 г., 22:13 ч. UTC

Печалби

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3.02.2026 г., 22:12 ч. UTC

Печалби

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3.02.2026 г., 22:10 ч. UTC

Печалби

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3.02.2026 г., 22:10 ч. UTC

Печалби

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3.02.2026 г., 22:10 ч. UTC

Пазарно говорене

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3.02.2026 г., 22:10 ч. UTC

Печалби

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3.02.2026 г., 22:09 ч. UTC

Печалби

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3.02.2026 г., 22:09 ч. UTC

Печалби

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

25.15% нагоре

12-месечна прогноза

Среден 32 USD 25.15%

Висок 37 USD

Нисък 30 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

111 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.